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Pmbolic Protection Devices
or Carotid Artery Stenting
s There a Difference Between Filter and Distal Occlusive Devices?
alf Zahn, MD, FESC,* Thomas Ischinger, MD, FESC,† Bernd Mark, MD,* Sabine Gass, MD,‡
we Zeymer, MD, FESC,* Wolfgang Schmalz, MD,§ Klaus Haerten, MD,
arl Eugen Hauptmann, MD,¶ Enz-Rüdiger von Leitner, MD,# Wolfgang Kasper, MD,**
lrich Tebbe, MD, FESC,†† Jochen Senges, MD, FACC, FESC,* for the Arbeitsgemeinschaft Leitende
ardiologische Krankenhausärzte (ALKK)
udwigshafen, München-Bogenhausen, Worms, Wesel, Trier, Hannover, Wiesbaden, and Detmold, Germany
OBJECTIVES We sought to compare the efficacy of a filter embolic protection device (F-EPD) and a distal
occlusive embolic protection device (DO-EPD) in patients undergoing carotid artery stenting
(CAS).
BACKGROUND The embolic protection device (EPD) may lower the periprocedural rate of cerebral ischemic
events during CAS. However, it is unclear whether there is a difference in effectiveness
between the different types of EPD.
METHODS We analyzed data from the Carotid Artery Stent (CAS) Registry.
RESULTS From July 1996 to July 2003, 1,734 patients were included in the prospective CAS Registry.
Of these patients, 729 patients were treated with an EPD, 553 (75.9%) with F-EPD, and 176
(24.1%) with DO-EPD. Patients treated with DO-EPD were more likely to be treated for
symptomatic stenosis (64.5% vs. 53.4%, p  0.011). The carotid lesions in patients treated
under DO-EPD seemed to be more complicated, as expressed by a higher proportion of
ulcers (p  0.035), severe calcification (p  0.039), a longer lesion length (p  0.025), and
a higher pre-interventional grade of stenosis (p  0.001). The median duration of the CAS
intervention was 30 min in the DO-EPD group, compared with 48 min in the filter group
(p  0.001). No differences in clinical events rate between the two groups of protection
devices were observed. Multivariate analysis on the occurrence of the combined end point of
in-hospital death or stroke found no difference between filter- and DO-EPD (4 of 176 [2.3%]
for DO-EPD vs. 10 of 551 [1.8%] for F-EPD; adjusted odds ratio  1.04, 95% confidence
interval 0.24 to 4.44; p  0.958).
CONCLUSIONS Filter EPD is the currently preferred method of EPD in clinical practice. Both F-EPD and
DO-EPD seem to be equally effective during CAS. (J Am Coll Cardiol 2005;45:1769–74)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.067© 2005 by the American College of Cardiology Foundation
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earotid artery stenting (CAS) increasingly emerges as an
lternative to carotid endarterectomy (CEA) for the treat-
ent of carotid stenoses (1–3). Both CEA and CAS carry
he burden of a small but clinically important rate of
eriprocedural complications—mainly, cerebral ischemic
vents.
Embolic protection devices (EPDs) may lower the rate of
psilateral ischemic events during CAS. This hypothesis is
upported by data from registries (4–6), as well as an
nalysis from the Endarterectomy Versus Angioplasty in
atients With Symptomatic Severe Carotid Stenosis (EVA-
S) trial (7). However, there are no data from randomized,
ontrolled clinical trials on this issue.
Embolic protection can be achieved by different types of
evices, such as filter embolic protection devices (F-EPD),
From the *Herzzentrum, Kardiologie, Ludwigshafen; †Städtisches Klinikum,
ardiologie, München-Bogenhausen; ‡Städtisches Klinikum, Neurologie, Ludwig-
hafen; §Stadtkrankenhaus, Kardiologie, Worms; Marienkrankenhaus, Kardiologie,
esel; ¶Krankenhaus der Barmherzigen Brüder, Kardiologie, Trier; #Klinikum
iloah, Kardiologie, Hannover; **St. Josefs Hospital, Kardiologie, Wiesbaden; and
†Klinikum Lippe-Detmold, Kardiologie, Detmold, Germany. Institutions and
eople who participated in the ALKK CAS Registry are listed elsewhere (4).c
Manuscript received December 16, 2004; revised manuscript received February 12,
005, accepted February 22, 2005.istal occlusion embolic protection devices (DO-EPD), and
everse flow devices (8–10). Experimental studies have
hown the ability of the different protection types to reduce
he amount of embolized material (11–14). However, until
ow, there are only data from randomized trials from the
oronary circulation for the treatment of saphenous vein
ypass grafts with percutaneous coronary interventions,
howing that F-EPD is as effective as DO-EPD in reducing
schemic events in a clinical scenario (15,16).
To determine the use and compare the effectiveness of
-EPD and DO-EPD during CAS, we analyzed the data
f the prospective Carotid Artery Stent (CAS) Registry of
he German Arbeitsgemeinschaft Leitende Kardiologische
rankenhausärzte (ALKK).
ETHODS
he CAS Registry of the ALKK is an ongoing registry that
as initiated in 1996; it has been described in detail
reviously (4). In brief, all interventions were prospectively
nrolled in the registry. All complications occurring in the
atheter room and during the in-hospital phase were doc-
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Embolic Protection Devices for Carotid Stenting June 7, 2005:1769–74mented. All data from the initiation in 1996 until the end
f July 2003 were analyzed for this report.
atient selection. All patients undergoing CAS for a
arotid stenosis at the participating hospitals were consid-
red for this analysis. Patients with symptomatic carotid
tenoses had a history of an ipsilateral stroke, at least one
ransient ischemic attack (TIA), or an episode of amaurosis
ugax. In these patients, an angiographically documented
tenosis 70%, according to the diagnostic criteria of the
orth American Symptomatic Carotid Endarterectomy
rial (NASCET) (17), was suggested to be an indication
or an intervention. In the case of asymptomatic patients, a
tenosis 80% was suggested as an indication for an
ntervention. The decision to treat a given patient was left to
he treating physician.
efinitions. Amaurosis fugax was defined as retinal isch-
mia with transient monocular blindness, and a TIA as a
ocal neurologic deficit that resolved spontaneously within
4 h. Stroke was defined as a loss of neurologic function
aused by an ischemic or hemorrhagic event, with residual
ymptoms at least 24 h after onset. A minor stroke was
iagnosed if symptoms disappeared within one week after
nset, and a major stroke if symptoms persisted for at least
ore than one week after onset.
No differentiation between ischemic, hemorrhagic, and
trokes with unknown etiology and no quantification of the
everity of stroke (such as the National Institutes of Health
troke Scale (18), besides its reversibility, were made.
End points were evaluated by a neurologist either imme-
iately at the occurrence of symptoms or at the end of the
ospital stay. We did not separately evaluate 30-day
ollow-up end points. The combined clinical end point of all
eaths and all strokes was prospectively defined as the
rimary end point.
he CAS procedure. The CAS procedure was performed
ccording to the standard protocol of each participating
enter.
tatistics. DATA COLLECTION. Every participating center
as committed by written consent to include each patient
uring the study period. The patients gave informed con-
ent for the processing of their anonymous data.
ATA ANALYSIS. Absolute numbers and percentages are
omputed to describe the patient population. Median values
Abbreviations and Acronyms
ALKK  Arbeitsgemeinschaft Leitende
Kardiologische Krankenhausärzte
CAS  carotid artery stenting
CEA  carotid endarterectomy
CI  confidence interval
DO-EPD  distal occlusive embolic protection device
EPD  embolic protection device
F-EPD  filter embolic protection device
OR  odds rationd quartiles are computed as appropriate. Categorical (alues were compared by the chi-square test, and crude odds
atios (ORs) with 95% confidence intervals (CIs) were
omputed. Continuous variables were compared by the
wo-tailed Wilcoxon rank-sum test. Logistic regression
nalysis was used to analyze selection of the use of F-EPD
nstead of DO-EPD. The following variables were exam-
ned: age (dichotomized to age 70 and 70 years),
ender, presence of thrombus, symptomatic carotid stenosis,
revious carotid intervention (CAS or surgery), caseload of
he hospitals for CAS, and year of inclusion. Logistic
egression analyses were also used to adjust for factors
nfluencing the combined clinical end point of all deaths and
ll strokes. The following variables were examined: age
dichotomized to age70 and70 years), gender, presence
f coronary heart disease, presence of symptomatic carotid
tenosis, previous carotid intervention (CAS or CEA),
resence of thrombus, presence of calcified lesions, presence
f carotid ulcer, caseload of the hospitals (dichotomized to
35 and35 reported CAS/hospital), and type of EPD. A
econd regression analysis on this end point was performed
ith age and caseload as continuous variables. We used the
statistic to assess the association between predicted prob-
bilities and observed response of each logistic regression
odel. A p value 0.05 was considered significant. All p
alues are results of two-tailed tests. The calculations were
erformed using SAS, version 8.02 (Cary, North Carolina).
ESULTS
rom July 1996 to July 2003, 1,734 patients from 26
ospitals were included in the prospective CAS Registry. Of
29 patients treated with distal protection, with information
n the type of protection device used, 553 (75.9%) were
reated with F-EPD and 176 (24.1%) with DO-EPD. The
se of EPD grew rapidly over time. Initially, the DO-EPD
as used more frequently, but with the introduction of
-EPD, it became the predominantly used device (Fig. 1).
lthough the GuardWire (Medtronic, Santa Rosa, Califor-
ia) was the only DO-EPD used in our registry, different
ypes of filters were used, as shown in Figure 2.
atient characteristics. Patients treated with DO-EPD
ere more likely to be treated for symptomatic stenosis
64.5% vs. 53.4%, p  0.011). However, they had a lower
revalence of previous carotid artery dilation (0% vs. 4.3%,
 0.005). The prevalence of concomitant diseases in both
roups is also given in Table 1.
esion and interventional characteristics. Lesions in pa-
ients treated with DO-EPD seemed to be more compli-
ated, as demonstrated by a higher proportion of ulcers (p
.035), severe calcification (p  0.039), a longer lesion
ength (p 0.025), and a higher pre-interventional grade of
tenosis (p  0.001). Pre-dilation without embolic protec-
ion was more often performed in the DO-EPD group
53% vs. 26.5%, p  0.001). The median duration of the
AS intervention was 18 min longer in the F-EPD groupp  0.001) (Table 2).
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June 7, 2005:1769–74 Embolic Protection Devices for Carotid Stentingelection of type of EPD. A logistic regression model
nalysis on the factors being independently associated with
he use of a filter instead of DO-EPD revealed the year of
mplantation (the most current years associated with a more
requent use of filters) to be the most powerful predictor
Table 3).
oncomitant medication and clinical events. No differ-
nce in the use of aspirin, ticlopidine or clopidogrel,
henprocoumon, and statins was found between the two
roups. However, angiotensin-converting enzyme inhibitors
p  0.002) and beta-blockers (p  0.006) were more often
rescribed in patients treated with DO-EPD during CAS
Table 4).
No differences in clinical event rates between the two
roups of EPD were observed (Table 4). Logistic regression
nalysis on the occurrence of in-hospital death or stroke,
djusting for possible confounding parameters, found no
ifference between DO-EPD and F-EPD (2.3% vs. 1.8%,
espectively; multivariable OR 1.04, 95% CI 0.24 to 4.44;
 0.958; c 0.688). This result did not change if age and
aseload were included as a continuous variable in the
ultivariate regression model. In patients with symptomatic
tenoses, the hospital rates of death or any stroke were 3.6%
n the DO-EPD group and 2.6% in the F-EPD group (p
.74). In asymptomatic patients, the corresponding rates
ere 0% versus 1.3% (p  1.0).
igure 1. Development in the use of different embolic protection devices (
istal occlusive embolic protection device; open bars  no distal protectioeFigure 2. Use of different filter devices.ISCUSSION
ajor findings of current analysis. Our study in a large
eries of patients undergoing CAS with different EPD
hows that currently F-EPD is by far the most preferred
PD. The type of protection device was not associated with
ifferences in acute clinical outcome during CAS.
election of type of protection device and interventional
haracteristics. The DO-EPD was the first EPD that
ecame commercially available. With the introduction of
lter devices, it rapidly conquered the market, being used
n 90% of protected CAS in 2003 in our registry. We
ound no other major important factor besides the year of
ecruitment that was associated with the use of F-EPD
nstead of DO-EPD. This predilection for F-EPD must
ave been driven by practical or marketing reasons, for
here are no data on the superiority of filters over
O-EPD during CAS. One factor in favor of filters is
he avoidance of complete interruption of the blood
tream via the internal carotid artery caused by DO-
PD. Such an interruption of blood flow is associated
ith temporal neurologic deficits in 5% of cases (19).
urthermore, the interruption of blood flow also makes
n angiographic guidance of the stent implantation more
ifficult. One advantage of DO-EPD may be that even
ery small particles can be captured, whereas in the case
f filter devices, small particles can pass the filter mem-
rane. However, the clinical relevance of this difference
as not been determined yet. A third type of EPD—the
everse flow system (12,20)—was not used in our registry.
herefore, we cannot comment on it.
The median duration of the CAS intervention was 30
in in the DO-EPD group, compared with 48 min in the
lter group (p 0.001). The reason for this may be that the
emporal occlusion of the internal carotid artery by DO-
PD puts the investigator under time pressure to quickly
erminate the intervention in order to avoid cerebral isch-
over time. Hatched bars  filter embolic protection device; solid bars mic symptoms of the patient.
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Embolic Protection Devices for Carotid Stenting June 7, 2005:1769–74linical events with filter versus DO-EPD. Although
here are only data from randomized clinical trials on the
se of EPD in saphenous vein graft interventions (15,16),
he principle of embolic protection during CAS seems so
onvincing that these devices have already conquered the
arket. As shown previously (4), our data suggest a small
Table 1. Baseline Characteristics and Concom
Age (yrs)*
Male gender 1
Symptomatic carotid stenosis 1
Kind of ipsilateral symptoms
(in symptomatic patients)
Amaurosis fugax
TIA
Stroke
Previous carotid artery surgery
Previous carotid artery dilation
Concomitant diseases
Coronary heart disease 1
Previous myocardial infarction
Peripheral arterial disease
Heart failure (NYHA functional
class III)†
Atrial fibrillation†
Chronic obstructive pulmonary disease†
Arterial hypertension†
Diabetes mellitus†
Hyperlipidemia†
Current smoker†
*Median values and quartiles. †Data available only in a subs
DO-EPD  distal occlusive embolic protection device;
Heart Association; TIA  transient ischemic attack.
Table 2. Carotid Lesion and Interventional Ch
D
(
Location of target stenosis
Right carotid artery 82/
Bilateral intervention 2/
Lesion characteristics
Restenosis after surgery or dilation* 3
Thrombus visible 17/
Ulcer 72/
Severe calcification 59/
Length 10 mm 104/
Bifurcation involved 92/
Percent stenosis before
intervention†
Interventional characteristics
Intervention not performed 0/
Pre-dilation necessary 80/
Maximal balloon diameter (mm)
Maximal balloon pressure (mm hg)
Stent implantation 176/
Stent length (mm)†
Numbers of dilations
Percent stenosis after intervention†
Duration of procedure (min)†*Data available only in a subset of patients. †Median values and q
Abbreviations as in Table 1.ut significant reduction of embolic events with the use of
hese devices during CAS: all nonfatal strokes and all
eaths with (2.1%) versus without (4.9%) protection
evices (p  0.004). This finding is confirmed by other
egistry data (5,6) and the clinical alert from the EVA-3S
rial (7).
Diseases
-EPD
176)
F-EPD
(n  553) p Value
0 (63–75) 70 (63–76) 0.734
6 (69.3%) 398/553 (72.0%) 0.498
2 (64.5%) 273/511 (53.4%) 0.011
1 (17.1%) 42/273 (15.4%) 0.674
1 (47.8%) 124/273 (45.4%) 0.678
1 (42.3%) 111/273 (40.7%) 0.761
5 (10.3%) 46/536 (8.6%) 0.494
5 (0.0%) 23/536 (4.3%) 0.005
5 (77.7%) 336/531 (63.3%) 0.001
5 (44.6%) 159/528 (30.1%) 0.001
5 (26.9%) 145/527 (27.5%) 0.866
3 (0.0%) 15/372 (4.0%) 0.081
4 (4.1%) 35/377 (9.3%) 0.139
4 (2.7%) 5/374 (1.3%) 0.387
3 (98.6%) 337/380 (88.7%) 0.009
4 (59.5%) 105/376 (27.9%) 0.001
4 (93.2%) 315/375 (84.0%) 0.039
4 (43.2%) 114/374 (30.5%) 0.032
atients.
 filter embolic protection device; NYHA  New York
teristics
PD
76)
F-EPD
(n  553) p Value
6.6%) 262/551 (47.6%) 0.824
.4%) 7/551 (1.3%) 0.889
.0%) 26/401 (6.5%) 0.409
1.4%) 74/409 (18.1%) 0.059
8.3%) 157/409 (38.4%) 0.035
9.6%) 124/409 (30.3%) 0.039
9.8%) 243/409 (59.4%) 0.025
1.7%) 224/409 (54.8%) 0.141
0–95) 90 (80–90) 0.001
%) 0/553 (0%) —
3.0%) 111/419 (26.5%) 0.001
–6) 5 (5–5.5) 0.001
2–16) 10 (9–14) 0.001
00.0%) 547/553 (98.9%) 0.165
4–40) 30 (30–40) 0.001
–2) 1 (1–2) 0.592
–10) 10 (0–20) 0.001
2–43) 48 (35–60) 0.001itant
DO
(n 
7
22/17
11/17
19/11
53/11
47/11
18/17
0/17
36/17
78/17
47/17
0/7
3/7
2/7
72/7
44/7
69/7
32/7
et of parac
O-E
n  1
176 (4
176 (1
/75 (4
149 (1
149 (4
149 (3
149 (6
149 (6
90 (9
176 (0
151 (5
5 (5
14 (1
176 (1
30 (2
1 (1
1 (1
30 (2uartiles.
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June 7, 2005:1769–74 Embolic Protection Devices for Carotid StentingHowever, there are no data comparing the clinical effec-
iveness of F-EPD versus DO-EPD during CAS. In our
tudy, the combined clinical end point of death or stroke
as 2.3% in patients treated with DO-EPD versus 1.8% in
AS patients treated with F-EPD (p  0.700). After
djusting for confounding parameters, the multivariable OR
as 1.04 (95% CI 0.24 to 4.44; p 0.958). There were also
o significant differences in the occurrence of the different
ypes of ipsilateral ischemic events.
Experimental data showed that different types of EPD
an reduce the rate of emboli (11,12). An experimental
tudy by Müller-Hülsbek et al. (21) comparing F-EPD with
O-EPD showed no differences in the rate of embolization
n the internal carotid artery, but there was a difference in
he embolization rates in the external carotid artery. A
urther investigation of the same group, including different
ypes of filters, showed significant differences concerning
he embolization rates between the investigated filters (13).
n in vivo study of Rogers et al. (22) demonstrated that the
nvestigational Medtronic AVE filter EPD could retrieve
articulate during saphenous vein graft stenting in a similar
Table 3. Multivariate Model of Predictors of t
Embolic Protection Devices (c  0.746)
Year of inclusion (1996–2003, per yr)
Previous myocardial infarction
Patients treated/hospital: 35 (median)
Presence of thrombus
Male gender
Symptomatic carotid stenosis
Age 65 yrs
Previous carotid intervention (surgery or dilation)
CI  confidence interval; OR  odds ratio.
able 4. Hospital Medication and Hospital Events
DO-EPD
(n  176)
ospital medication
Aspirin 163/174 (93.7%
Ticlopidine/clopidogrel 157/160 (98.1%
Phenprocoumon 9/79 (11.4%
Statins* 63/73 (86.3%
Angiotensin-converting enzyme inhibitors* 60/73 (82.2%
Beta-blockers* 57/73 (78.1%
ospital events
Ipsilateral amaurosis fugax 0/176 (0.0%)
Ipsilateral TIA 7/176 (4.0%)
Ipsilateral stroke 4/176 (2.3%)
Minor 2/176 (1.1%)
Major 2/176 (1.1%)
Ipsilateral stroke/TIA/amaurosis fugax 11/176 (6.3%)
Any ischemic event contralateral 1/176 (0.6%)
Myocardial infarction 0/176 (0.0%)
Death 0/176 (0.0%)
All nonfatal strokes and all death 4/176 (2.3%)
Any death/stroke/TIA/amaurosis fugax 11/176 (6.3%)Data available only in a subset of patients.
Abbreviations as in Tables 1 and 3.mount and character as the PercuSurge Medtronic Guard-
ire.
The randomized, controlled clinical trial that estab-
ished the effectiveness of EPD was done using a DO-
PD for the percutaneous treatment of coronary saphe-
ous venous bypass grafts (15). Further trials comparing
ifferent EPDs revealed conflicting results: some showed
noninferiority of the investigated EPD (16,23), and
nother failed to demonstrate noninferiority (24), as
ompared with the reference DO-EPD (i.e., the Guard-
ire by Medtronic). These trials show that the different
ypes of EPD (F-EPD, DO-EPD, or reverse flow de-
ices) have about the same potential in reducing the
mount and characteristics of embolizing particulate.
owever, due to differences in the design of these
evices, each one has to demonstrate its own efficacy.
tudy limitations. Because the CAS Registry of the
LKK is an observational study, it is not possible to control
otally for the selection of patients to be treated with one of
he two types of EPD. In particular, the later introduction
f F-EPD into clinical practice may have interfered with the
se of Filter Instead of Distal Occlusive
Wald’s
hi-Square
Adjusted OR
(95% CI) p Value
67.58 2.60 (2.07–3.27) 0.001
9.90 0.49 (0.31–0.76) 0.002
2.63 0.54 (0.26–1.14) 0.105
1.66 1.50 (0.81–2.79) 0.198
1.42 1.33 (0.83–2.13) 0.234
1.29 0.77 (0.49–1.21) 0.256
0.57 1.21 (0.74–1.97) 0.450
0.44 1.29 (0.61–2.69) 0.506
F-EPD
(n  553) p Value OR (95% CI)
510/538 (94.8%) 0.573
517/526 (98.3%) 0.890
20/356 (5.6%) 0.063
291/372 (78.2%) 0.118
238/374 (63.6%) 0.002
231/377 (61.3%) 0.006
2/551 (0.4%) 0.424 —
11/551 (2.0%) 0.141 0.49 (0.19–1.29)
8/551 (1.5%) 0.457 0.63 (0.19–2.13)
3/551 (0.5%) 0.408 0.48 (0.08–2.87)
6/551 (1.1%) 0.958 0.96 (0.19–4.79)
20/551 (3.6%) 0.134 0.57 (0.27–1.20)
6/551 (1.1%) 0.538 1.93 (0.23–16.1)
0/551 (0.0%) — —
2/553 (0.4%) 0.424 —
10/551 (1.8%) 0.700 0.80 (0.25–2.57)
22/551 (4.0%) 0.210 0.62 (0.30–1.31)he U
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Embolic Protection Devices for Carotid Stenting June 7, 2005:1769–74rowing experience of the investigators, a factor that cannot
e controlled for. However, given the low complication
ates in both groups (F-EPD vs. DO-EPD), it is very
nlikely that there are clinically relevant differences between
he two types of EPD.
Also, different types of F-EPD, as well as different stages
f their development, were combined and could not be
valuated separately due to low numbers. Therefore, no
onclusions on equivalence or superiority between the dif-
erent F-EPD devices can be drawn.
We obtained only data until hospital discharge. There-
ore, it may be difficult to compare our data to 30-day
utcome data of other studies. However, clinical events are
xtremely low after the first days of stent implantation
25,26).
eprint requests and correspondence: Dr. Ralf Zahn, Herzzen-
rum Ludwigshafen, Dept. of Cardiology, Bremserstrasse 79,
-67063 Ludwigshafen, Germany. E-mail: erzahn@aol.com.
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